Literature DB >> 25666766

Benign versus atypical meningiomas: risk factors predicting recurrence.

Arkadiusz Nowak1, Tomasz Dziedzic2, Piotr Krych2, Tomasz Czernicki2, Przemysław Kunert2, Andrzej Marchel2.   

Abstract

OBJECTIVE: The aim of the study is to determine which clinic, radiologic, and surgical characteristics of benign and atypical meningioma are associated with tumor progression.
METHODS: 335 patients who underwent gross-total resection of intracranial benign and atypical meningiomas between 2000 and 2009 were followed during the period of at least 3 years. Clinical, radiological and surgical features possibly associated with progression-free survival and influencing tumor recurrence were assessed.
RESULTS: 291 lesions were benign (WHO Grade I) and 44 were atypical (WHO Grade II). In the median follow-up period of 82 months 34 meningiomas recurred. The 3-, 5- and 10-year progression-free survival (PFS) rates for benign and atypical tumors were 99.7 and 81.4%, 97.5 and 69.7%, 87.5 and 69.7%, respectively. In a Kaplan-Meier analysis subpial plane of surgical dissection (pial invasion) was associated with increased tumor progression both in benign (p=0.0084) and atypical cohort (p=0.0104), and bone involvement (p=0.0033) and peritumoral brain edema (p=0.0073) were associated with increased tumor progression only in atypical meningiomas. In a multivariate analysis pial invasion and WHO Grade II type were significantly associated with tumor recurrence. All recurrences in atypical meningioma group occurred within 4 years of the surgical resection.
CONCLUSION: Pial invasion is an important predictor of tumor recurrence in benign and atypical meningiomas. In atypical meningiomas bone involvement and large peritumoral brain edema are associated with increased tumor progression.
Copyright © 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Atypical meningioma; Benign meningioma; Pial invasion; Prognosis; Tumor recurrence

Mesh:

Year:  2014        PMID: 25666766     DOI: 10.1016/j.pjnns.2014.11.003

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN: 0028-3843            Impact factor:   1.621


  14 in total

1.  MRI predictive score of pial vascularization of supratentorial intracranial meningioma.

Authors:  Guillaume Friconnet; Victor Hugo Espíndola Ala; Kevin Janot; Waleed Brinjikji; Clément Bogey; Leslie Lemnos; Henri Salle; Suzana Saleme; Charbel Mounayer; Aymeric Rouchaud
Journal:  Eur Radiol       Date:  2019-04-08       Impact factor: 5.315

2.  Meningioma recurrence rates following treatment: a systematic analysis.

Authors:  Victor Lam Shin Cheung; Albert Kim; Arjun Sahgal; Sunit Das
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

3.  WHO grade of intracranial meningiomas differs with respect to patient's age, location, tumor size and peritumoral edema.

Authors:  Anne Ressel; Susanne Fichte; Michael Brodhun; Steffen K Rosahl; Ruediger Gerlach
Journal:  J Neurooncol       Date:  2019-10-01       Impact factor: 4.130

4.  Gene Expression Signatures Identify Biologically Homogenous Subgroups of Grade 2 Meningiomas.

Authors:  Zsolt Zador; Alexander P Landry; Ashirbani Saha; Michael D Cusimano
Journal:  Front Oncol       Date:  2020-11-05       Impact factor: 6.244

5.  Impact of postoperative radiotherapy on recurrence of primary intracranial atypical meningiomas.

Authors:  Naureen Keric; Darius Kalasauskas; Christian F Freyschlag; Jens Gempt; Martin Misch; Alicia Poplawski; Nicole Lange; Ali Ayyad; Claudius Thomé; Peter Vajkoczy; Bernhard Meyer; Florian Ringel
Journal:  J Neurooncol       Date:  2020-01-03       Impact factor: 4.130

6.  Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma.

Authors:  Shirin Karimi; Manav V Vyas; Lior Gonen; Raha Tabasinejad; Quinn T Ostrom; Jill Barnholtz-Sloan; Suganth Suppiah; Gelareh Zadeh; Kenneth Aldape
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

7.  Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas.

Authors:  Agbolahan A Sofela; David A Hilton; Sylwia Ammoun; Daniele Baiz; Claire L Adams; Emanuela Ercolano; Michael D Jenkinson; Kathreena M Kurian; Mario Teo; Peter C Whitfield; Felix Sahm; C Oliver Hanemann
Journal:  Int J Mol Sci       Date:  2021-01-08       Impact factor: 5.923

Review 8.  Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis.

Authors:  Se-Woong Chun; Kyung Min Kim; Min-Sung Kim; Ho Kang; Yun-Sik Dho; Youngbeom Seo; Jin Wook Kim; Yong Hwy Kim; Chul-Kee Park
Journal:  Radiat Oncol       Date:  2021-02-17       Impact factor: 3.481

9.  Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence.

Authors:  B R Ongaratti; C B O Silva; G Trott; T Haag; C G S Leães; N P Ferreira; M C Oliveira; J F S Pereira-Lima
Journal:  Braz J Med Biol Res       Date:  2016-03-18       Impact factor: 2.590

10.  Predictors of early progression of surgically treated atypical meningiomas.

Authors:  Karol P Budohoski; James Clerkin; Christopher P Millward; Philip J O'Halloran; Mueez Waqar; Seamus Looby; Adam M H Young; Mathew R Guilfoyle; Diana Fitzroll; Abel Devadass; Kieren Allinson; Michael Farrell; Mohsen Javadpour; Michael D Jenkinson; Thomas Santarius; Ramez W Kirollos
Journal:  Acta Neurochir (Wien)       Date:  2018-06-30       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.